UBS Group
CYCN icon

UBS Group’s Cyclerion Therapeutics CYCN Stock Holding History

UBS Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.26K Buy
3,391
+3,015
+802% +$4.29K ﹤0.01% 8812
2025
Q4 		$478 Buy
376
+327
+667% +$584 ﹤0.01% 9942
2025
Q3 		$113 Sell
49
-9,678
-99% -$26.3K ﹤0.01% 9898
2025
Q2 		$28.3K Sell
9,727
-3,274
-25% -$9.78K ﹤0.01% 8206
2025
Q1 		$32.5K Buy
13,001
+3,334
+34% +$9.93K ﹤0.01% 7888
2024
Q4 		$31.1K Buy
9,667
+9,522
+6,567% +$26.5K ﹤0.01% 7576
2024
Q3 		$376 Sell
145
-2,561
-95% -$7.53K ﹤0.01% 8969
2024
Q2 		$6.22K Buy
2,706
+182
+7% +$517 ﹤0.01% 7938
2024
Q1 		$8.08K Buy
2,524
+296
+13% +$946 ﹤0.01% 7347
2023
Q4 		$7.46K Buy
2,228
+1,952
+707% +$5.64K ﹤0.01% 7624
2023
Q3 		$944 Buy
276
+90
+48% +$324 ﹤0.01% 8215
2023
Q2 		$766 Sell
186
-526
-74% -$2.73K ﹤0.01% 8111
2023
Q1 		$6.18K Sell
712
-199
-22% -$2.51K ﹤0.01% 7949
2022
Q4 		$12K Buy
+911
New +$10.8K ﹤0.01% 8322
2022
Q2 		– Sell
-182
Closed -$4K – 10405
2022
Q1 		$4K Buy
+182
New +$4.38K ﹤0.01% 9283
2021
Q4 		– Sell
-177
Closed -$11K – 10322
2021
Q3 		$11K Buy
177
+163
+1,164% +$10.7K ﹤0.01% 7872
2021
Q2 		$1K Sell
14
-220
-94% -$13.8K ﹤0.01% 9139
2021
Q1 		$13K Sell
234
-37
-14% -$2.78K ﹤0.01% 7729
2020
Q4 		$17K Buy
271
+251
+1,255% +$17.1K ﹤0.01% 7052
2020
Q3 		$2K Sell
20
-319
-94% -$36.5K ﹤0.01% 7646
2020
Q2 		$40K Sell
339
-369
-52% -$30.9K ﹤0.01% 6055
2020
Q1 		$38K Sell
708
-708
-50% -$50.5K ﹤0.01% 6038
2019
Q4 		$77K Sell
1,416
-531
-27% -$49.6K ﹤0.01% 6125
2019
Q3 		$471K Buy
1,947
+1,055
+118% +$228K ﹤0.01% 4620
2019
Q2 		$205K Buy
+892
New +$252K ﹤0.01% 4899

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

UBS Group's CYCN Position: Q1 2026 in Review

UBS Group increased its Cyclerion Therapeutics (CYCN) stake by 802% in Q1 2026, buying an estimated $4.29K and bringing the position to 3,391 shares worth $5.26K. The position accounts for ﹤0.01% of the portfolio, ranked #8812.

UBS Group first reported a position in CYCN in Q2 2019 and has held it in 25 quarters since. The position peaked at $471K in Q3 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • UBS Group held 3,391 shares of Cyclerion Therapeutics worth $5.26K as of Q1 2026.
  • UBS Group bought 3,015 Cyclerion Therapeutics shares in Q1 2026, an estimated $4.29K.
  • Cyclerion Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8812 holding.
  • UBS Group first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • UBS Group's Cyclerion Therapeutics position peaked at $471K in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.